The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail


Takeda Global R&D Centre Europe LimitedEU/1/12/794/001

Main Information

Trade NameAdcetris
Active SubstancesBrentuximab vedotin
Dosage FormPowder for concentrate for solution for infusion
Licence HolderTakeda Global R&D Centre Europe Limited
Licence NumberEU/1/12/794/001

Group Information

ATC CodeL01XC Monoclonal antibodies
L01XC12 brentuximab vedotin


Licence Issued25/10/2012
Legal statusNot applicable
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back